Tim Osborne
Patrimonio netto: 252 132 $ in data 31/05/2026
Patrimonio netto: 252 132 $ in data 31/05/2026
Tim Osborne currently works at Forward Air Corp., as Executive Vice President-Operations from 2024.
Dr. Osborne also formerly worked at the University of California, Irvine, as Principal and Select BioVentures LLC, as Advisor.
Dr. Osborne received his undergraduate degree from King University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 15/03/2026 | 23.831 ( 0,08% ) | 252 132 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| FORWARD AIR CORPORATION | Direttore operativo | 01/01/2024 |
| Società | Posizione | Fine |
|---|---|---|
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Investitore di Private Equity | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Forward Air Corp.
Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale